Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...

Dr Pradeep highlights warning signs of heart failure, including increased urination at night, swollen ankles, and breathlessness.

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

Martha Gulati, MD, explains how bias and underrepresentation in research lead to misdiagnosis of HFpEF in women and delays in ...

Cytokinetics has announced that the FDA has approved MYQORZO tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with oHCM .

Aficamten, a first-in-class cardiac myosin inhibitor, offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...

Selene Yeager is a health and fitness writer with over 25 years of experience. Her work has appeared in Shape, O, the Oprah Magazine, Men’s Health, Women's Health, Marie Claire, Good Housekeeping, ...